BenevolentAI
investment highlights market leader in drug discovery with and technologically differentiated approach robust with patents on drug pipeline and copyright and trade secrets on our technology platform cant platform scale and internal capability flexible business model with revenue opportunities to extend cash runway rich portfolio of drug programmes all generated from the benevolent platform near and medium term key value in points high value and successful commercial partnership proving strategic validation world renowned board and experienced leadership team | BenevolentAI
Company
Deck date
October 2022
Slide
26 of 46
Similar slides by BenevolentAI
Investor Day
September 2022
Related slides by other companies
Investor Day
February 2024
Investor Presentation
December 2023
Results
November 2022
Results
February 2023
Other recent decks by BenevolentAI
Investor Presentation
September 2024
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io